close

Fenwick Represents Gritstone Oncology in the IP Due Diligence of its IPO and Strategic Collaboration

October 16, 2018

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Fenwick & West represented Gritstone Oncology, a next-generation personalized cancer immunotherapy company, in the intellectual property due diligence aspect of its initial public offering and its strategic collaboration with Bluebird Bio to research, develop and commercialize products for the treatment of cancer using cell therapy. More information about Gritstone’s strategic collaboration can be obtained from their press release.

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even slightly believable. If you are going to use a passage of Lorem Ipsum, you need to be sure there isn't anything embarrassing hidden in the middle of text.

The Fenwick team was led by intellectual property attorneys Michael Shuster and Kevin Kabler.

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even slightly believable. If you are going to use a passage of Lorem Ipsum, you need to be sure there isn't anything embarrassing hidden in the middle of text.

​​​​​​